Floatz logo

ro7119929

Secondary Liver Cancer

Hoffmann-La RochePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Secondary Liver Cancer cohort.

Asset / SponsorPhaseRating
Eloxatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Capecitabine
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
SACUBITRIL VALSARTAN
Silesian Centre for Heart Diseases
Phase 4BB
Irinotecan
Ludwig-Maximilians - University of Munich
Phase 2BB
Everolimus
Gynaecologisch Oncologisch Centrum Zuid
Phase 2/3B

View all 21 →

Same molecule, other indications

ro7119929 is also rated in:

hepatocellular carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
biliary tract cancerDormant
CC
Indicative ·
42 / 100
View asset →
Liver MetastasesDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →